Quarter-end position / Version 1 · published

ORAMED PHARMACEUTICALS INC.

Reporting manager / owner
Aquamarine Financial (Cayman) Ltd
Relationship
Associated institution
Record date
2026-06-30
Date meaning
Original Form 13F report period
CUSIP / security class
68403P203 / COM NEW
Quantity
2,512,175 shares
Reported value / amount
$12,083,562
Weight / denominator
0.667113% · Calculated: issuer/class value divided by the complete original reported table; not personal wealth
Quarter-end reported price
Not disclosed; not purchase cost
Derived value per reported unit
4.81; reported value ÷ quantity, not observed market price
Source-reported activity
Not disclosed
Coverage
Complete original information table grouped by CUSIP and security class
Reviewed by
DeepSeek AI
Published
22 Oct 2026

Original regulatory disclosure; 1 original filing line(s) grouped within this issuer/class. Absence from a disclosed table is not private account verification.

Reporting-entity association

Original filing attribution · 1 line(s)

Reporting manager: Aquamarine Financial (Cayman) Ltd. 13F HOLDINGS REPORT. These are reported investment-discretion relationships, not proof of beneficial ownership or a personal account. Each original line is counted once, including lines naming multiple managers.

ORIGINAL LINEREPORTED QUANTITY / VALUEOTHER MANAGER / DISCRETIONVOTING AUTHORITY
122,512,175 shares$12,083,562No included manager referencedOriginal field: Not stated · Discretion: SOLESole 2,512,175Shared 0 · None 0

Read the full editorial review note ↗

Copy a dated citation ↗

Sources.

Aquamarine Financial (Cayman) Ltd — 13F-HR — 2026-06-30 · U.S. SEC EDGAR · Published 12 Aug 2026 · Collected 22 Oct 2026 · Evidence details ↗

Version history.

Version 1 · published · 22 Oct 2026 · Full review note

Suggest a correction ↗

Copy a dated citation.

If copying is unavailable, select the text above and copy it manually.